BioCentury
ARTICLE | Clinical News

Evolutec dropping rEV131

January 4, 2007 1:52 AM UTC

Evolutec (LSE:EVC) said it will discontinue development of rEV131 after the histamine binding protein missed the primary endpoint of reduction in inflammation at 14 days post-surgery vs. placebo in a double-blind, U.S. Phase II trial to treat post-surgical inflammation of the eye in 150 patients. Last month, rEV131 failed a Phase IIb trial in 300 patients with allergic rhinitis. ...